Endometriosis: A Global Strategic Business Report
San Jose, California (PRWEB) March 29, 2012
Follow us on LinkedIn – As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. The disease represents one of the major causes of female infertility constituting for about 30% of infertility cases in women. The global endometriosis market is characterized by weak market conditions due to lack of disease awareness and diagnostic techniques, poor efficacy and safety profiles of the presently available therapies, and a weak product pipeline. The market is presently comprised of only off-label and generic drugs, categorized under four major therapeutic categories, including Gonadotropin - Releasing Hormone (GnRH) agonists, Progestins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and contraceptives or birth control pills. The present drugs mainly provide short-term relief of disease symptoms, without providing an absolute cure for endometriosis. The drugs presently available in the market are lowest on efficacy and safety profiles and may lead to adverse effects, which primarily include loss of bone density as well as several menopause-like side effects. Hence, there exists a huge unmet need for novel and effective drugs in the market, with improved safety profiles. This would be further driven in future by the increasing incidence rates of endometriosis due to environmental factors, rising awareness of the disease, and improved diagnosis.
The future looks promising for endometriosis, with increasing efforts being made in research and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease and alternative methods are being readily accepted. Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis. Genetic and biomolecular diagnostic tests are also being trailed.
The US represents the largest market for endometriosis globally, followed by Europe, as stated by a new market research report on Endometriosis. Developing markets, including Asia-Pacific, Latin America, and the Middle East are forecast to exhibit the fastest growth, at a compounded annualized growth of about 6.4% during the analysis period. Endometriosis affects about 10% women of reproductive age in Asia, which is quite high in comparison to the prevalence of the disease in other continents. The traditional Chinese medicine, based on a 3,000 year-old holistic representation of personalized health maintenance using various forms of therapy such as acupuncture and herbs, is increasingly finding overwhelming acceptance in Asia. In addition, the traditional Chinese medicine is being used by several women in the US, Europe and Australia.
Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis. The emergence of certain other promising innovative drugs, including Repros Therapeutics’ Proellex, Neurocrine’s Elagolix, and Bayer HealthCare Pharmaceuticals’ Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future. Drugs that are expected to drive future market growth include Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486. Angiogenesis therapy is also expected to become a key potential treatment option for endometriosis. In terms of diagnosis, Laproscopy is the gold standard in the diagnosis of endometriosis.
Major players profiled in the report include Abbott Laboratories, AEterna Zentaris Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Eli Lilly and Company, Meditrina Pharmaceuticals Inc., Neurocrine Biosciences Inc., Pfizer Inc., Repros Therapeutics Inc., among others.
The research report titled “Endometriosis: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive overview of endometriosis market, current market trends, principal growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Endometriosis treatment for the years 2009 through 2017 for the following geographic markets - US, Canada, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/